1. Int J Mol Sci. 2023 Aug 10;24(16):12634. doi: 10.3390/ijms241612634.

Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is 
Sphingosine-1-Phosphate at the Helm?

Martín-Hernández D(1)(2), Muñoz-López M(1)(2), Tendilla-Beltrán H(3), Caso 
JR(1)(2), García-Bueno B(1)(2), Menchén L(4)(5), Leza JC(1)(2).

Author information:
(1)Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad 
Complutense de Madrid (UCM), Instituto de Investigación Hospital 12 de Octubre 
(i+12), Instituto Universitario de Investigación en Neuroquímica (IUIN), 28040 
Madrid, Spain.
(2)Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud 
Carlos III (CIBERSAM, ISCIII), 28029 Madrid, Spain.
(3)Laboratorio de Neuropsiquiatría, Instituto de Fisiología, Benemérita 
Universidad Autónoma de Puebla (BUAP), 72570 Puebla, Mexico.
(4)Servicio de Aparato Digestivo, Hospital General Universitario Gregorio 
Marañón, Departamento de Medicina, Universidad Complutense, Instituto de 
Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.
(5)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y 
Digestivas, Instituto de Salud Carlos III (CIBEREHD, ISCIII), 28029 Madrid, 
Spain.

Over the past few decades, extensive research has shed light on immune 
alterations and the significance of dysfunctional biological barriers in 
psychiatric disorders. The leaky gut phenomenon, intimately linked to the 
integrity of both brain and intestinal barriers, may play a crucial role in the 
origin of peripheral and central inflammation in these pathologies. 
Sphingosine-1-phosphate (S1P) is a bioactive lipid that regulates both the 
immune response and the permeability of biological barriers. Notably, S1P-based 
drugs, such as fingolimod and ozanimod, have received approval for treating 
multiple sclerosis, an autoimmune disease of the central nervous system (CNS), 
and ulcerative colitis, an inflammatory condition of the colon, respectively. 
Although the precise mechanisms of action are still under investigation, the 
effectiveness of S1P-based drugs in treating these pathologies sparks a debate 
on extending their use in psychiatry. This comprehensive review aims to delve 
into the molecular mechanisms through which S1P modulates the immune system and 
brain/intestinal barrier functions. Furthermore, it will specifically focus on 
psychiatric diseases, with the primary objective of uncovering the potential of 
innovative therapies based on S1P signaling.

DOI: 10.3390/ijms241612634
PMCID: PMC10454107
PMID: 37628815 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no conflict of interest.